The Novel Lipid Emulsion Vegaven Is Well Tolerated and Elicits Distinct Biological Actions Compared With a Mixed-Oil Lipid Emulsion Containing Fish Oil: A Parenteral Nutrition Trial in Piglets
Vegaven is well tolerated in this piglet model of PN, demonstrating distinct biological actions compared with SMOFlipid, namely lower liver, pancreas, and brain inflammation, enhanced insulin signaling, and improved whole body glucose control.
Authors
- Camila Schultz Marcolla (ORCID: https://orcid.org/0000-0002-0010-4841)
- Martin Hersberger (ORCID: https://orcid.org/0000-0002-4472-329X)
- Eliana Lucchinetti (ORCID: https://orcid.org/0000-0003-3338-1279)
- Mirielle Pauline (ORCID: https://orcid.org/0000-0001-8700-0035)
- Justine Turner (ORCID: https://orcid.org/0000-0002-3517-636X)
- Paul W. Wales (ORCID: https://orcid.org/0000-0001-7206-735X)
- Stefanie D. Krämer (ORCID: https://orcid.org/0000-0002-0426-4340)
- Phing‐How Lou (ORCID: https://orcid.org/0000-0003-2090-1132)
- Eytan Wine (ORCID: https://orcid.org/0000-0002-3458-4142)
- Akash Chakravarty
- Catherine J. Field (ORCID: https://orcid.org/0000-0001-7285-4767)
- Michael Zaugg (ORCID: https://orcid.org/0000-0002-2016-8973)
- Pamela R. Wizzard
Institutions
- Cincinnati Children's Hospital Medical Center (US)
- University of Alberta (CA)
- University of Zurich (CH)
- University Children's Hospital Zurich (CH)
Publication Details
- Journal
- Journal of Nutrition
- Published
- 2024-11-04
- DOI
- https://doi.org/10.1016/j.tjnut.2024.10.047
- Citations
- 4
- Primary Topic
- Diet and metabolism studies
- Type
- article
- Field-Weighted Citation Impact
- 1.31
Funders
- University of Alberta
- Canadian Institutes of Health Research